Levi & Korsinsky, LLP has launched an investigation into Oculis Holding AG (NASDAQ: OCS) for potential federal securities law violations. This follows Oculis's disclosure that its pivotal DIAMOND trials for the OCS-01 DME program failed, leading to the abandonment of FDA filing plans and a stock drop of over 23%. The investigation focuses on earlier SEC filings that presented the program as progressing toward regulatory approval despite ultimately failing.

This article compiles various trade ideas and technical analyses for QUALCOMM (NEO:QCOM), offering both bullish and bearish perspectives. Analysts discuss potential price movements, technical indicators like RSI and moving averages, and the impact of the NXP deal and upcoming earnings reports on the stock's future performance. The common themes include gap filling, head and shoulder patterns, and considerations for short-term and long-term investment strategies for QCOM.

Roche and Nurix Therapeutics have announced a global collaboration to co-develop and co-commercialize bexobrutideg (NX-5948), an investigational BTK degrader, for various conditions including B-cell malignancies, immunology, and neurology. Nurix will receive an upfront payment of USD 700 million and potentially up to USD 2.3 billion in milestone payments. Bexobrutideg, which targets and eliminates the BTK protein, is expected to enter Phase 3 clinical trials for chronic lymphocytic leukaemia (CLL) in summer 2026, offering a potential best-in-class treatment option.

Nurix Therapeutics has announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral BTK degrader, for malignant hematology, immunology, and neurology indications. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in milestone payments. The agreement includes a 50/50 profit and loss split for U.S. commercialization and tiered ex-U.S. royalties for Nurix.

Roche has entered into an exclusive global licensing and collaboration agreement with Nurix Therapeutics for the co-development and co-commercialisation of bexobrutideg (NX-5948), an oral BTK degrader. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in total deal value through various milestones. The collaboration aims to advance bexobrutideg for B-cell malignancies, immunology, and neurology, with Phase 3 CLL trials planned for summer 2026.

KeyCorp raised its Q2 2026 EPS estimate for Diamondback Energy (NASDAQ: FANG) to $5.63 from $5.20, while maintaining an "Overweight" rating and a $225 price target. This increase follows Diamondback Energy's latest quarterly results, which surpassed expectations with an EPS of $4.23 and revenue of $4.24 billion. The company also recently increased its quarterly dividend to $1.10 per share, resulting in an annualized payout of $4.40 and a dividend yield of approximately 2.3%.

Wall Street Zen has upgraded Nano Nuclear Energy (NASDAQ:NNE) from "strong sell" to "sell" while the overall analyst consensus remains a "Moderate Buy" with a $47.00 price target. The stock has shown high volatility, trading between a 52-week low of $18.93 and a high of $60.87, and significant insider selling, including a $43.1 million sale over the past 90 days, has been reported. Despite the volatility and insider sales, the company reported earnings that beat analyst estimates.

NatWest Group has committed to no further branch closure announcements for its NatWest, Royal Bank of Scotland, and Ulster Bank brands until at least 2029. While nine branches are set to close later this year as part of an existing program, these will be the final closures for several years. The bank plans to invest £50 million in its network over 2026/2027 to modernize existing locations, improve customer experience, expand mobile branch services, and explore new branch openings where there is clear demand for face-to-face banking.

Nurix Therapeutics has entered a global collaboration with Roche to develop and commercialize bexobrutideg, an oral degrader of Bruton’s tyrosine kinase (BTK), for B-cell malignancies and other immune-mediated diseases. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in milestone payments, with shared development costs and profits in the U.S. This partnership aims to leverage Nurix's expertise in targeted protein degradation and Roche's commercial capabilities to address significant unmet medical needs.

Nayax Ltd. recently launched an in-house AI-powered personalization engine for retailers, aiming to deepen merchant relationships and enhance targeted consumer engagement. This development aligns with Nayax's strategy to shift towards a software and data platform, focusing on recurring revenue from processing and SaaS fees. Investors should consider how this AI integration could influence growth, while also being mindful of potential regulatory and data privacy risks and the ongoing tension between revenue guidance and thinner margins.